Sells equipment, consumables and services for biological medicine production, life sciences research and medical diagnostics to drug and biotechnology companies, research organizations, and hospitals and laboratories.
10-K for FY2025, filed Feb 24, 2026The Biotechnology segment offers a broad range of equipment, consumables, software and services that are primarily used by customers to…View ↗
The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to…View ↗
The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference…View ↗
Danaher sells equipment and consumables in one-time sales; services, extended warranties and operating-type leases generate revenue over their terms, while some long-term contracts generate revenue as work progresses.
10-K for FY2025, filed Feb 24, 2026Revenue Recognition—The Company derives revenues primarily from the sale of life sciences research, biopharmaceutical drug production and…View ↗
Certain of the Company’s revenues relate to operating-type lease (“OTL”) arrangements. Leases are outside the scope of ASC 606 and are…View ↗
The Company’s products and services primarily consist of life sciences research, biopharmaceutical drug production and medical diagnostic…View ↗
10-K for FY2025, filed Feb 24, 2026
FY2025 revenue by product or service ↗$24.6B
10-K for FY2025, filed Feb 24, 2026
$24.6B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Recurring
Mix
10-K for FY2025, filed Feb 24, 2026 |
82%
FY2022: 78%
|
Recurring, FY2025
$20.1B Sources
|
Mix |
|
Nonrecurring
Mix
10-K for FY2025, filed Feb 24, 2026 |
18%
FY2022: 22%
|
Nonrecurring, FY2025
$4.4B Sources
|
Mix |
Pharmaceutical and biotechnology companies, research organizations, hospitals and laboratories buy Danaher's products through its sales teams and independent distributors.
10-K for FY2025, filed Feb 24, 2026The bioprocessing business is a leading provider of technologies, consumables, services and solutions that advance, accelerate and…View ↗
Customers served by the Biotechnology segment select products based on several factors, including product quality and reliability, the…View ↗
The life sciences instruments business enables the discovery, development and manufacture of new therapies. Key product areas include…View ↗
Customers served by the Diagnostics segment select products based on a number of factors, including product quality and reliability, the…View ↗
Yes. It kept 15 cents of every revenue dollar as net income in FY2025 and turned 21 cents into free cash flow.
10-K for FY2025, filed Feb 24, 2026
$4.7BView ↗
10-K for FY2025, filed Feb 24, 2026
$3.6BView ↗
10-K for FY2025, filed Feb 24, 2026
$5.3BView ↗
10-Q for Q3 FY2026, filed Oct 21, 2026
Open tableView ↗
8-K, filed Oct 21, 2026
For full year 2026, the Company is increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.57 to…View ↗
8-K, filed Aug 3, 2026
WASHINGTON, D.C., August 3, 2026 – PR Newswire – Danaher Corporation (NYSE: DHR) (“Danaher” or “the Company”) announced that the Company’s…View ↗
Flat. Revenue was $24.6B in FY2025, about the same as the $24.8B of FY2021.
Segment portfolio
The older report includes Environmental & Applied Solutions as a segment, while the latest describes biotechnology, life sciences and diagnostics segments.
10-K for FY2022, filed Feb 22, 2023 10-K for FY2025, filed Feb 24, 2026Danaher is a global science and technology innovator committed to helping customers solve complex challenges and improving quality of life…View ↗
Danaher is a global science and technology innovator committed to accelerating the power of science and technology to improve human health.…View ↗
Loading...